nodes	percent_of_prediction	percent_of_DWPC	metapath
Procainamide—Sunitinib—pancreatic cancer	0.609	1	CrCtD
Procainamide—Metoclopramide—Sunitinib—pancreatic cancer	0.239	1	CrCrCtD
Procainamide—ACHE—Irinotecan—pancreatic cancer	0.0313	0.333	CbGbCtD
Procainamide—SLC22A3—Irinotecan—pancreatic cancer	0.0304	0.324	CbGbCtD
Procainamide—BCHE—Irinotecan—pancreatic cancer	0.0189	0.201	CbGbCtD
Procainamide—CYP2D6—Tamoxifen—pancreatic cancer	0.00588	0.0626	CbGbCtD
Procainamide—CYP2D6—Erlotinib—pancreatic cancer	0.005	0.0532	CbGbCtD
Procainamide—CYP2D6—Doxorubicin—pancreatic cancer	0.00246	0.0262	CbGbCtD
Procainamide—Sunitinib—STK11—pancreatic cancer	0.000733	0.597	CrCbGaD
Procainamide—Sunitinib—KDR—pancreatic cancer	0.000264	0.215	CrCbGaD
Procainamide—Lidocaine—EGFR—pancreatic cancer	0.000231	0.188	CrCbGaD
Procainamide—Bradycardia—Sunitinib—pancreatic cancer	0.000167	0.00483	CcSEcCtD
Procainamide—Lightheadedness—Docetaxel—pancreatic cancer	0.000167	0.00481	CcSEcCtD
Procainamide—Hepatomegaly—Doxorubicin—pancreatic cancer	0.000164	0.00474	CcSEcCtD
Procainamide—Pleural effusion—Epirubicin—pancreatic cancer	0.000164	0.00474	CcSEcCtD
Procainamide—Dysgeusia—Tamoxifen—pancreatic cancer	0.000164	0.00472	CcSEcCtD
Procainamide—Eosinophilia—Fluorouracil—pancreatic cancer	0.00016	0.00463	CcSEcCtD
Procainamide—Neutropenia—Irinotecan—pancreatic cancer	0.000158	0.00456	CcSEcCtD
Procainamide—Neutropenia—Gemcitabine—pancreatic cancer	0.000154	0.00444	CcSEcCtD
Procainamide—Angioedema—Tamoxifen—pancreatic cancer	0.000153	0.0044	CcSEcCtD
Procainamide—Flushing—Sunitinib—pancreatic cancer	0.000153	0.0044	CcSEcCtD
Procainamide—Cardiac disorder—Sunitinib—pancreatic cancer	0.000153	0.0044	CcSEcCtD
Procainamide—Pleural effusion—Doxorubicin—pancreatic cancer	0.000152	0.00438	CcSEcCtD
Procainamide—Hepatic failure—Docetaxel—pancreatic cancer	0.000151	0.00434	CcSEcCtD
Procainamide—Renal failure—Irinotecan—pancreatic cancer	0.000148	0.00428	CcSEcCtD
Procainamide—Chills—Sunitinib—pancreatic cancer	0.000147	0.00425	CcSEcCtD
Procainamide—Renal failure—Gemcitabine—pancreatic cancer	0.000144	0.00417	CcSEcCtD
Procainamide—Atrial fibrillation—Docetaxel—pancreatic cancer	0.000143	0.00412	CcSEcCtD
Procainamide—Arthralgia—Tamoxifen—pancreatic cancer	0.000142	0.0041	CcSEcCtD
Procainamide—Myalgia—Tamoxifen—pancreatic cancer	0.000142	0.0041	CcSEcCtD
Procainamide—Renal impairment—Docetaxel—pancreatic cancer	0.000142	0.0041	CcSEcCtD
Procainamide—Arthralgia—Erlotinib—pancreatic cancer	0.000141	0.00406	CcSEcCtD
Procainamide—Myalgia—Erlotinib—pancreatic cancer	0.000141	0.00406	CcSEcCtD
Procainamide—Discomfort—Tamoxifen—pancreatic cancer	0.00014	0.00405	CcSEcCtD
Procainamide—Dysgeusia—Sunitinib—pancreatic cancer	0.00014	0.00404	CcSEcCtD
Procainamide—Cardiac failure—Docetaxel—pancreatic cancer	0.000139	0.004	CcSEcCtD
Procainamide—Lethargy—Docetaxel—pancreatic cancer	0.000138	0.00398	CcSEcCtD
Procainamide—Bradycardia—Irinotecan—pancreatic cancer	0.000138	0.00398	CcSEcCtD
Procainamide—Agranulocytosis—Gemcitabine—pancreatic cancer	0.000137	0.00395	CcSEcCtD
Procainamide—Oliguria—Epirubicin—pancreatic cancer	0.000136	0.00393	CcSEcCtD
Procainamide—Agranulocytosis—Fluorouracil—pancreatic cancer	0.000135	0.00389	CcSEcCtD
Procainamide—Thrombocytopenia—Tamoxifen—pancreatic cancer	0.000133	0.00385	CcSEcCtD
Procainamide—Shock—Erlotinib—pancreatic cancer	0.000133	0.00383	CcSEcCtD
Procainamide—Thrombocytopenia—Erlotinib—pancreatic cancer	0.000132	0.00381	CcSEcCtD
Procainamide—Angioedema—Sunitinib—pancreatic cancer	0.000131	0.00377	CcSEcCtD
Procainamide—Anorexia—Tamoxifen—pancreatic cancer	0.00013	0.00375	CcSEcCtD
Procainamide—Anorexia—Erlotinib—pancreatic cancer	0.000129	0.00371	CcSEcCtD
Procainamide—Oliguria—Doxorubicin—pancreatic cancer	0.000126	0.00364	CcSEcCtD
Procainamide—Ventricular tachycardia—Epirubicin—pancreatic cancer	0.000126	0.00363	CcSEcCtD
Procainamide—Cardiac disorder—Irinotecan—pancreatic cancer	0.000126	0.00362	CcSEcCtD
Procainamide—Flushing—Irinotecan—pancreatic cancer	0.000126	0.00362	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Tamoxifen—pancreatic cancer	0.000124	0.00358	CcSEcCtD
Procainamide—Convulsion—Sunitinib—pancreatic cancer	0.000124	0.00358	CcSEcCtD
Procainamide—Abdominal pain upper—Docetaxel—pancreatic cancer	0.000124	0.00356	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Erlotinib—pancreatic cancer	0.000123	0.00355	CcSEcCtD
Procainamide—Cardiac disorder—Gemcitabine—pancreatic cancer	0.000122	0.00353	CcSEcCtD
Procainamide—Myalgia—Sunitinib—pancreatic cancer	0.000122	0.00351	CcSEcCtD
Procainamide—Arthralgia—Sunitinib—pancreatic cancer	0.000122	0.00351	CcSEcCtD
Procainamide—Chills—Irinotecan—pancreatic cancer	0.000121	0.0035	CcSEcCtD
Procainamide—Decreased appetite—Tamoxifen—pancreatic cancer	0.000119	0.00342	CcSEcCtD
Procainamide—Chills—Gemcitabine—pancreatic cancer	0.000118	0.00341	CcSEcCtD
Procainamide—Decreased appetite—Erlotinib—pancreatic cancer	0.000117	0.00338	CcSEcCtD
Procainamide—Ventricular tachycardia—Doxorubicin—pancreatic cancer	0.000116	0.00336	CcSEcCtD
Procainamide—Shock—Sunitinib—pancreatic cancer	0.000115	0.00331	CcSEcCtD
Procainamide—Thrombocytopenia—Sunitinib—pancreatic cancer	0.000114	0.0033	CcSEcCtD
Procainamide—Rash maculo-papular—Epirubicin—pancreatic cancer	0.000114	0.0033	CcSEcCtD
Procainamide—Gastrointestinal pain—Tamoxifen—pancreatic cancer	0.000111	0.00322	CcSEcCtD
Procainamide—Anorexia—Sunitinib—pancreatic cancer	0.000111	0.00321	CcSEcCtD
Procainamide—Gastrointestinal pain—Erlotinib—pancreatic cancer	0.00011	0.00318	CcSEcCtD
Procainamide—Ill-defined disorder—Irinotecan—pancreatic cancer	0.000109	0.00315	CcSEcCtD
Procainamide—Neutropenia—Docetaxel—pancreatic cancer	0.000109	0.00315	CcSEcCtD
Procainamide—Urticaria—Tamoxifen—pancreatic cancer	0.000108	0.00312	CcSEcCtD
Procainamide—Abdominal pain—Tamoxifen—pancreatic cancer	0.000108	0.00311	CcSEcCtD
Procainamide—Body temperature increased—Erlotinib—pancreatic cancer	0.000107	0.00308	CcSEcCtD
Procainamide—Abdominal pain—Erlotinib—pancreatic cancer	0.000107	0.00308	CcSEcCtD
Procainamide—Ill-defined disorder—Gemcitabine—pancreatic cancer	0.000107	0.00307	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Sunitinib—pancreatic cancer	0.000106	0.00307	CcSEcCtD
Procainamide—Malaise—Irinotecan—pancreatic cancer	0.000106	0.00307	CcSEcCtD
Procainamide—Rash maculo-papular—Doxorubicin—pancreatic cancer	0.000106	0.00305	CcSEcCtD
Procainamide—Malaise—Gemcitabine—pancreatic cancer	0.000104	0.00299	CcSEcCtD
Procainamide—Renal failure—Docetaxel—pancreatic cancer	0.000102	0.00296	CcSEcCtD
Procainamide—Hepatic failure—Epirubicin—pancreatic cancer	0.000102	0.00293	CcSEcCtD
Procainamide—Decreased appetite—Sunitinib—pancreatic cancer	0.000101	0.00293	CcSEcCtD
Procainamide—Hypersensitivity—Tamoxifen—pancreatic cancer	0.0001	0.0029	CcSEcCtD
Procainamide—Discomfort—Irinotecan—pancreatic cancer	9.91e-05	0.00286	CcSEcCtD
Procainamide—Asthenia—Tamoxifen—pancreatic cancer	9.78e-05	0.00282	CcSEcCtD
Procainamide—Convulsion—Fluorouracil—pancreatic cancer	9.78e-05	0.00282	CcSEcCtD
Procainamide—Myalgia—Gemcitabine—pancreatic cancer	9.77e-05	0.00282	CcSEcCtD
Procainamide—Arthralgia—Gemcitabine—pancreatic cancer	9.77e-05	0.00282	CcSEcCtD
Procainamide—Agranulocytosis—Docetaxel—pancreatic cancer	9.73e-05	0.00281	CcSEcCtD
Procainamide—Confusional state—Irinotecan—pancreatic cancer	9.7e-05	0.0028	CcSEcCtD
Procainamide—Asthenia—Erlotinib—pancreatic cancer	9.68e-05	0.00279	CcSEcCtD
Procainamide—Discomfort—Gemcitabine—pancreatic cancer	9.66e-05	0.00279	CcSEcCtD
Procainamide—Pruritus—Tamoxifen—pancreatic cancer	9.64e-05	0.00278	CcSEcCtD
Procainamide—Myalgia—Fluorouracil—pancreatic cancer	9.61e-05	0.00277	CcSEcCtD
Procainamide—Renal impairment—Epirubicin—pancreatic cancer	9.59e-05	0.00277	CcSEcCtD
Procainamide—Gastrointestinal pain—Sunitinib—pancreatic cancer	9.55e-05	0.00275	CcSEcCtD
Procainamide—Pruritus—Erlotinib—pancreatic cancer	9.54e-05	0.00275	CcSEcCtD
Procainamide—Discomfort—Fluorouracil—pancreatic cancer	9.49e-05	0.00274	CcSEcCtD
Procainamide—Shock—Irinotecan—pancreatic cancer	9.46e-05	0.00273	CcSEcCtD
Procainamide—Thrombocytopenia—Irinotecan—pancreatic cancer	9.42e-05	0.00272	CcSEcCtD
Procainamide—Hepatic failure—Doxorubicin—pancreatic cancer	9.39e-05	0.00271	CcSEcCtD
Procainamide—Cardiac failure—Epirubicin—pancreatic cancer	9.35e-05	0.0027	CcSEcCtD
Procainamide—Diarrhoea—Tamoxifen—pancreatic cancer	9.33e-05	0.00269	CcSEcCtD
Procainamide—Lethargy—Epirubicin—pancreatic cancer	9.31e-05	0.00269	CcSEcCtD
Procainamide—Confusional state—Fluorouracil—pancreatic cancer	9.29e-05	0.00268	CcSEcCtD
Procainamide—Abdominal pain—Sunitinib—pancreatic cancer	9.23e-05	0.00266	CcSEcCtD
Procainamide—Body temperature increased—Sunitinib—pancreatic cancer	9.23e-05	0.00266	CcSEcCtD
Procainamide—Diarrhoea—Erlotinib—pancreatic cancer	9.23e-05	0.00266	CcSEcCtD
Procainamide—Thrombocytopenia—Gemcitabine—pancreatic cancer	9.17e-05	0.00265	CcSEcCtD
Procainamide—Anorexia—Irinotecan—pancreatic cancer	9.17e-05	0.00264	CcSEcCtD
Procainamide—Thrombocytopenia—Fluorouracil—pancreatic cancer	9.02e-05	0.0026	CcSEcCtD
Procainamide—Dizziness—Tamoxifen—pancreatic cancer	9.01e-05	0.0026	CcSEcCtD
Procainamide—Hypotension—Irinotecan—pancreatic cancer	8.99e-05	0.00259	CcSEcCtD
Procainamide—Anorexia—Gemcitabine—pancreatic cancer	8.93e-05	0.00258	CcSEcCtD
Procainamide—Dizziness—Erlotinib—pancreatic cancer	8.92e-05	0.00257	CcSEcCtD
Procainamide—Renal impairment—Doxorubicin—pancreatic cancer	8.87e-05	0.00256	CcSEcCtD
Procainamide—Anorexia—Fluorouracil—pancreatic cancer	8.78e-05	0.00253	CcSEcCtD
Procainamide—Hypotension—Gemcitabine—pancreatic cancer	8.75e-05	0.00253	CcSEcCtD
Procainamide—Flushing—Docetaxel—pancreatic cancer	8.68e-05	0.00251	CcSEcCtD
Procainamide—Cardiac disorder—Docetaxel—pancreatic cancer	8.68e-05	0.00251	CcSEcCtD
Procainamide—Cardiac arrest—Epirubicin—pancreatic cancer	8.68e-05	0.0025	CcSEcCtD
Procainamide—Vomiting—Tamoxifen—pancreatic cancer	8.67e-05	0.0025	CcSEcCtD
Procainamide—Cardiac failure—Doxorubicin—pancreatic cancer	8.65e-05	0.0025	CcSEcCtD
Procainamide—Lethargy—Doxorubicin—pancreatic cancer	8.61e-05	0.00249	CcSEcCtD
Procainamide—Hypotension—Fluorouracil—pancreatic cancer	8.61e-05	0.00248	CcSEcCtD
Procainamide—Hypersensitivity—Sunitinib—pancreatic cancer	8.6e-05	0.00248	CcSEcCtD
Procainamide—Vomiting—Erlotinib—pancreatic cancer	8.58e-05	0.00247	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	8.54e-05	0.00246	CcSEcCtD
Procainamide—Chills—Docetaxel—pancreatic cancer	8.4e-05	0.00242	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	8.39e-05	0.00242	CcSEcCtD
Procainamide—Asthenia—Sunitinib—pancreatic cancer	8.38e-05	0.00242	CcSEcCtD
Procainamide—Decreased appetite—Irinotecan—pancreatic cancer	8.36e-05	0.00241	CcSEcCtD
Procainamide—Abdominal pain upper—Epirubicin—pancreatic cancer	8.33e-05	0.0024	CcSEcCtD
Procainamide—Pruritus—Sunitinib—pancreatic cancer	8.26e-05	0.00238	CcSEcCtD
Procainamide—Decreased appetite—Gemcitabine—pancreatic cancer	8.14e-05	0.00235	CcSEcCtD
Procainamide—Nausea—Tamoxifen—pancreatic cancer	8.1e-05	0.00234	CcSEcCtD
Procainamide—Cardiac arrest—Doxorubicin—pancreatic cancer	8.03e-05	0.00232	CcSEcCtD
Procainamide—Nausea—Erlotinib—pancreatic cancer	8.01e-05	0.00231	CcSEcCtD
Procainamide—Decreased appetite—Fluorouracil—pancreatic cancer	8.01e-05	0.00231	CcSEcCtD
Procainamide—Diarrhoea—Sunitinib—pancreatic cancer	7.99e-05	0.0023	CcSEcCtD
Procainamide—Dysgeusia—Docetaxel—pancreatic cancer	7.98e-05	0.0023	CcSEcCtD
Procainamide—Feeling abnormal—Irinotecan—pancreatic cancer	7.93e-05	0.00229	CcSEcCtD
Procainamide—Gastrointestinal pain—Irinotecan—pancreatic cancer	7.86e-05	0.00227	CcSEcCtD
Procainamide—Eosinophilia—Epirubicin—pancreatic cancer	7.81e-05	0.00225	CcSEcCtD
Procainamide—Dizziness—Sunitinib—pancreatic cancer	7.72e-05	0.00223	CcSEcCtD
Procainamide—Feeling abnormal—Gemcitabine—pancreatic cancer	7.72e-05	0.00223	CcSEcCtD
Procainamide—Abdominal pain upper—Doxorubicin—pancreatic cancer	7.71e-05	0.00222	CcSEcCtD
Procainamide—Abdominal pain—Irinotecan—pancreatic cancer	7.6e-05	0.00219	CcSEcCtD
Procainamide—Body temperature increased—Irinotecan—pancreatic cancer	7.6e-05	0.00219	CcSEcCtD
Procainamide—Feeling abnormal—Fluorouracil—pancreatic cancer	7.59e-05	0.00219	CcSEcCtD
Procainamide—Vomiting—Sunitinib—pancreatic cancer	7.42e-05	0.00214	CcSEcCtD
Procainamide—Body temperature increased—Gemcitabine—pancreatic cancer	7.41e-05	0.00214	CcSEcCtD
Procainamide—Neutropenia—Epirubicin—pancreatic cancer	7.37e-05	0.00213	CcSEcCtD
Procainamide—Urticaria—Fluorouracil—pancreatic cancer	7.32e-05	0.00211	CcSEcCtD
Procainamide—Body temperature increased—Fluorouracil—pancreatic cancer	7.28e-05	0.0021	CcSEcCtD
Procainamide—Eosinophilia—Doxorubicin—pancreatic cancer	7.22e-05	0.00208	CcSEcCtD
Procainamide—Hypersensitivity—Irinotecan—pancreatic cancer	7.09e-05	0.00204	CcSEcCtD
Procainamide—Convulsion—Docetaxel—pancreatic cancer	7.06e-05	0.00204	CcSEcCtD
Procainamide—Arthralgia—Docetaxel—pancreatic cancer	6.94e-05	0.002	CcSEcCtD
Procainamide—Myalgia—Docetaxel—pancreatic cancer	6.94e-05	0.002	CcSEcCtD
Procainamide—Nausea—Sunitinib—pancreatic cancer	6.94e-05	0.002	CcSEcCtD
Procainamide—Renal failure—Epirubicin—pancreatic cancer	6.91e-05	0.00199	CcSEcCtD
Procainamide—Asthenia—Irinotecan—pancreatic cancer	6.9e-05	0.00199	CcSEcCtD
Procainamide—Neutropenia—Doxorubicin—pancreatic cancer	6.82e-05	0.00197	CcSEcCtD
Procainamide—Hypersensitivity—Fluorouracil—pancreatic cancer	6.79e-05	0.00196	CcSEcCtD
Procainamide—Asthenia—Gemcitabine—pancreatic cancer	6.72e-05	0.00194	CcSEcCtD
Procainamide—Confusional state—Docetaxel—pancreatic cancer	6.7e-05	0.00193	CcSEcCtD
Procainamide—Pruritus—Gemcitabine—pancreatic cancer	6.63e-05	0.00191	CcSEcCtD
Procainamide—Diarrhoea—Irinotecan—pancreatic cancer	6.58e-05	0.0019	CcSEcCtD
Procainamide—Agranulocytosis—Epirubicin—pancreatic cancer	6.56e-05	0.00189	CcSEcCtD
Procainamide—Shock—Docetaxel—pancreatic cancer	6.54e-05	0.00189	CcSEcCtD
Procainamide—Pruritus—Fluorouracil—pancreatic cancer	6.52e-05	0.00188	CcSEcCtD
Procainamide—Thrombocytopenia—Docetaxel—pancreatic cancer	6.51e-05	0.00188	CcSEcCtD
Procainamide—Bradycardia—Epirubicin—pancreatic cancer	6.43e-05	0.00185	CcSEcCtD
Procainamide—Diarrhoea—Gemcitabine—pancreatic cancer	6.41e-05	0.00185	CcSEcCtD
Procainamide—Renal failure—Doxorubicin—pancreatic cancer	6.39e-05	0.00185	CcSEcCtD
Procainamide—Dizziness—Irinotecan—pancreatic cancer	6.36e-05	0.00183	CcSEcCtD
Procainamide—Anorexia—Docetaxel—pancreatic cancer	6.34e-05	0.00183	CcSEcCtD
Procainamide—Diarrhoea—Fluorouracil—pancreatic cancer	6.3e-05	0.00182	CcSEcCtD
Procainamide—Hypotension—Docetaxel—pancreatic cancer	6.21e-05	0.00179	CcSEcCtD
Procainamide—Vomiting—Irinotecan—pancreatic cancer	6.11e-05	0.00176	CcSEcCtD
Procainamide—Dizziness—Fluorouracil—pancreatic cancer	6.09e-05	0.00176	CcSEcCtD
Procainamide—Agranulocytosis—Doxorubicin—pancreatic cancer	6.07e-05	0.00175	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	6.06e-05	0.00175	CcSEcCtD
Procainamide—Vomiting—Gemcitabine—pancreatic cancer	5.96e-05	0.00172	CcSEcCtD
Procainamide—Bradycardia—Doxorubicin—pancreatic cancer	5.95e-05	0.00172	CcSEcCtD
Procainamide—Cardiac disorder—Epirubicin—pancreatic cancer	5.86e-05	0.00169	CcSEcCtD
Procainamide—Flushing—Epirubicin—pancreatic cancer	5.86e-05	0.00169	CcSEcCtD
Procainamide—Vomiting—Fluorouracil—pancreatic cancer	5.86e-05	0.00169	CcSEcCtD
Procainamide—Decreased appetite—Docetaxel—pancreatic cancer	5.78e-05	0.00167	CcSEcCtD
Procainamide—Nausea—Irinotecan—pancreatic cancer	5.71e-05	0.00165	CcSEcCtD
Procainamide—Chills—Epirubicin—pancreatic cancer	5.66e-05	0.00163	CcSEcCtD
Procainamide—Nausea—Gemcitabine—pancreatic cancer	5.56e-05	0.00161	CcSEcCtD
Procainamide—Feeling abnormal—Docetaxel—pancreatic cancer	5.48e-05	0.00158	CcSEcCtD
Procainamide—Nausea—Fluorouracil—pancreatic cancer	5.47e-05	0.00158	CcSEcCtD
Procainamide—Gastrointestinal pain—Docetaxel—pancreatic cancer	5.44e-05	0.00157	CcSEcCtD
Procainamide—Flushing—Doxorubicin—pancreatic cancer	5.42e-05	0.00156	CcSEcCtD
Procainamide—Cardiac disorder—Doxorubicin—pancreatic cancer	5.42e-05	0.00156	CcSEcCtD
Procainamide—Dysgeusia—Epirubicin—pancreatic cancer	5.38e-05	0.00155	CcSEcCtD
Procainamide—Body temperature increased—Docetaxel—pancreatic cancer	5.26e-05	0.00152	CcSEcCtD
Procainamide—Abdominal pain—Docetaxel—pancreatic cancer	5.26e-05	0.00152	CcSEcCtD
Procainamide—Chills—Doxorubicin—pancreatic cancer	5.24e-05	0.00151	CcSEcCtD
Procainamide—Ill-defined disorder—Epirubicin—pancreatic cancer	5.1e-05	0.00147	CcSEcCtD
Procainamide—Dysgeusia—Doxorubicin—pancreatic cancer	4.98e-05	0.00144	CcSEcCtD
Procainamide—Malaise—Epirubicin—pancreatic cancer	4.95e-05	0.00143	CcSEcCtD
Procainamide—Hypersensitivity—Docetaxel—pancreatic cancer	4.9e-05	0.00141	CcSEcCtD
Procainamide—Asthenia—Docetaxel—pancreatic cancer	4.77e-05	0.00138	CcSEcCtD
Procainamide—Convulsion—Epirubicin—pancreatic cancer	4.76e-05	0.00137	CcSEcCtD
Procainamide—Ill-defined disorder—Doxorubicin—pancreatic cancer	4.72e-05	0.00136	CcSEcCtD
Procainamide—Pruritus—Docetaxel—pancreatic cancer	4.7e-05	0.00136	CcSEcCtD
Procainamide—Myalgia—Epirubicin—pancreatic cancer	4.68e-05	0.00135	CcSEcCtD
Procainamide—Arthralgia—Epirubicin—pancreatic cancer	4.68e-05	0.00135	CcSEcCtD
Procainamide—Discomfort—Epirubicin—pancreatic cancer	4.62e-05	0.00133	CcSEcCtD
Procainamide—Malaise—Doxorubicin—pancreatic cancer	4.58e-05	0.00132	CcSEcCtD
Procainamide—Diarrhoea—Docetaxel—pancreatic cancer	4.55e-05	0.00131	CcSEcCtD
Procainamide—Confusional state—Epirubicin—pancreatic cancer	4.52e-05	0.0013	CcSEcCtD
Procainamide—Shock—Epirubicin—pancreatic cancer	4.41e-05	0.00127	CcSEcCtD
Procainamide—Convulsion—Doxorubicin—pancreatic cancer	4.4e-05	0.00127	CcSEcCtD
Procainamide—Dizziness—Docetaxel—pancreatic cancer	4.4e-05	0.00127	CcSEcCtD
Procainamide—Thrombocytopenia—Epirubicin—pancreatic cancer	4.39e-05	0.00127	CcSEcCtD
Procainamide—Arthralgia—Doxorubicin—pancreatic cancer	4.33e-05	0.00125	CcSEcCtD
Procainamide—Myalgia—Doxorubicin—pancreatic cancer	4.33e-05	0.00125	CcSEcCtD
Procainamide—Discomfort—Doxorubicin—pancreatic cancer	4.28e-05	0.00123	CcSEcCtD
Procainamide—Anorexia—Epirubicin—pancreatic cancer	4.27e-05	0.00123	CcSEcCtD
Procainamide—Vomiting—Docetaxel—pancreatic cancer	4.23e-05	0.00122	CcSEcCtD
Procainamide—Hypotension—Epirubicin—pancreatic cancer	4.19e-05	0.00121	CcSEcCtD
Procainamide—Confusional state—Doxorubicin—pancreatic cancer	4.18e-05	0.00121	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	4.09e-05	0.00118	CcSEcCtD
Procainamide—Shock—Doxorubicin—pancreatic cancer	4.08e-05	0.00118	CcSEcCtD
Procainamide—Thrombocytopenia—Doxorubicin—pancreatic cancer	4.06e-05	0.00117	CcSEcCtD
Procainamide—Anorexia—Doxorubicin—pancreatic cancer	3.96e-05	0.00114	CcSEcCtD
Procainamide—Nausea—Docetaxel—pancreatic cancer	3.95e-05	0.00114	CcSEcCtD
Procainamide—Decreased appetite—Epirubicin—pancreatic cancer	3.9e-05	0.00112	CcSEcCtD
Procainamide—Hypotension—Doxorubicin—pancreatic cancer	3.88e-05	0.00112	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	3.78e-05	0.00109	CcSEcCtD
Procainamide—Feeling abnormal—Epirubicin—pancreatic cancer	3.7e-05	0.00107	CcSEcCtD
Procainamide—Gastrointestinal pain—Epirubicin—pancreatic cancer	3.67e-05	0.00106	CcSEcCtD
Procainamide—Decreased appetite—Doxorubicin—pancreatic cancer	3.61e-05	0.00104	CcSEcCtD
Procainamide—Urticaria—Epirubicin—pancreatic cancer	3.56e-05	0.00103	CcSEcCtD
Procainamide—Body temperature increased—Epirubicin—pancreatic cancer	3.54e-05	0.00102	CcSEcCtD
Procainamide—Abdominal pain—Epirubicin—pancreatic cancer	3.54e-05	0.00102	CcSEcCtD
Procainamide—Feeling abnormal—Doxorubicin—pancreatic cancer	3.42e-05	0.000986	CcSEcCtD
Procainamide—Gastrointestinal pain—Doxorubicin—pancreatic cancer	3.39e-05	0.000979	CcSEcCtD
Procainamide—Hypersensitivity—Epirubicin—pancreatic cancer	3.3e-05	0.000953	CcSEcCtD
Procainamide—Urticaria—Doxorubicin—pancreatic cancer	3.3e-05	0.000951	CcSEcCtD
Procainamide—Body temperature increased—Doxorubicin—pancreatic cancer	3.28e-05	0.000946	CcSEcCtD
Procainamide—Abdominal pain—Doxorubicin—pancreatic cancer	3.28e-05	0.000946	CcSEcCtD
Procainamide—Asthenia—Epirubicin—pancreatic cancer	3.22e-05	0.000928	CcSEcCtD
Procainamide—Pruritus—Epirubicin—pancreatic cancer	3.17e-05	0.000915	CcSEcCtD
Procainamide—Diarrhoea—Epirubicin—pancreatic cancer	3.07e-05	0.000885	CcSEcCtD
Procainamide—Hypersensitivity—Doxorubicin—pancreatic cancer	3.06e-05	0.000882	CcSEcCtD
Procainamide—Asthenia—Doxorubicin—pancreatic cancer	2.98e-05	0.000859	CcSEcCtD
Procainamide—Dizziness—Epirubicin—pancreatic cancer	2.97e-05	0.000856	CcSEcCtD
Procainamide—Pruritus—Doxorubicin—pancreatic cancer	2.94e-05	0.000847	CcSEcCtD
Procainamide—Vomiting—Epirubicin—pancreatic cancer	2.85e-05	0.000823	CcSEcCtD
Procainamide—Diarrhoea—Doxorubicin—pancreatic cancer	2.84e-05	0.000819	CcSEcCtD
Procainamide—Dizziness—Doxorubicin—pancreatic cancer	2.74e-05	0.000792	CcSEcCtD
Procainamide—Nausea—Epirubicin—pancreatic cancer	2.66e-05	0.000768	CcSEcCtD
Procainamide—Vomiting—Doxorubicin—pancreatic cancer	2.64e-05	0.000761	CcSEcCtD
Procainamide—Nausea—Doxorubicin—pancreatic cancer	2.46e-05	0.000711	CcSEcCtD
Procainamide—ACHE—Metabolism—SLC2A2—pancreatic cancer	7.89e-06	0.000348	CbGpPWpGaD
Procainamide—CHRM2—Regulation of Actin Cytoskeleton—KRAS—pancreatic cancer	7.88e-06	0.000348	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—ACVR1B—pancreatic cancer	7.86e-06	0.000347	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—ZNRF3—pancreatic cancer	7.86e-06	0.000347	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—CTNNB1—pancreatic cancer	7.82e-06	0.000346	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	7.81e-06	0.000345	CbGpPWpGaD
Procainamide—ACHE—Transmission across Chemical Synapses—HRAS—pancreatic cancer	7.79e-06	0.000344	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—TYMP—pancreatic cancer	7.78e-06	0.000344	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—CD44—pancreatic cancer	7.76e-06	0.000343	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	7.72e-06	0.000341	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—MMP9—pancreatic cancer	7.67e-06	0.000339	CbGpPWpGaD
Procainamide—CHRM2—SIDS Susceptibility Pathways—TNF—pancreatic cancer	7.65e-06	0.000338	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—HRAS—pancreatic cancer	7.64e-06	0.000337	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—PTHLH—pancreatic cancer	7.61e-06	0.000336	CbGpPWpGaD
Procainamide—BCHE—Metabolism—GLP1R—pancreatic cancer	7.54e-06	0.000333	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	7.53e-06	0.000333	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—GCG—pancreatic cancer	7.44e-06	0.000329	CbGpPWpGaD
Procainamide—BCHE—Metabolism—DPYD—pancreatic cancer	7.42e-06	0.000328	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—HRAS—pancreatic cancer	7.34e-06	0.000324	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—HRAS—pancreatic cancer	7.34e-06	0.000324	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—SHH—pancreatic cancer	7.29e-06	0.000322	CbGpPWpGaD
Procainamide—CHRM2—Regulation of Actin Cytoskeleton—PIK3CA—pancreatic cancer	7.24e-06	0.00032	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—IAPP—pancreatic cancer	7.2e-06	0.000318	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	7.13e-06	0.000315	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—SSTR3—pancreatic cancer	7.11e-06	0.000314	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—DTX1—pancreatic cancer	7.11e-06	0.000314	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—HRAS—pancreatic cancer	7.08e-06	0.000313	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—HRAS—pancreatic cancer	7.08e-06	0.000313	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—SRC—pancreatic cancer	7.07e-06	0.000312	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—AKT1—pancreatic cancer	7.05e-06	0.000312	CbGpPWpGaD
Procainamide—BCHE—Metabolism—SLC2A2—pancreatic cancer	7.04e-06	0.000311	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—STK11—pancreatic cancer	6.99e-06	0.000309	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—HRAS—pancreatic cancer	6.97e-06	0.000308	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	6.96e-06	0.000308	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—SST—pancreatic cancer	6.96e-06	0.000307	CbGpPWpGaD
Procainamide—BCHE—Transmission across Chemical Synapses—HRAS—pancreatic cancer	6.95e-06	0.000307	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—PTHLH—pancreatic cancer	6.91e-06	0.000305	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—PTCH1—pancreatic cancer	6.91e-06	0.000305	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—VEGFA—pancreatic cancer	6.89e-06	0.000304	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	6.86e-06	0.000303	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—STAT3—pancreatic cancer	6.82e-06	0.000301	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—SSTR1—pancreatic cancer	6.81e-06	0.000301	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—NRAS—pancreatic cancer	6.8e-06	0.0003	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—AKT1—pancreatic cancer	6.74e-06	0.000298	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—GLP1R—pancreatic cancer	6.73e-06	0.000297	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	6.72e-06	0.000297	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PPY—pancreatic cancer	6.68e-06	0.000295	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—DPYD—pancreatic cancer	6.62e-06	0.000293	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—SSTR2—pancreatic cancer	6.56e-06	0.00029	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—AKT1—pancreatic cancer	6.48e-06	0.000286	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—AKT1—pancreatic cancer	6.48e-06	0.000286	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—CNR1—pancreatic cancer	6.42e-06	0.000284	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CCKBR—pancreatic cancer	6.33e-06	0.00028	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—TGFB1—pancreatic cancer	6.32e-06	0.000279	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—SST—pancreatic cancer	6.32e-06	0.000279	CbGpPWpGaD
Procainamide—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	6.3e-06	0.000278	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—SLC2A2—pancreatic cancer	6.28e-06	0.000278	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—GLP1R—pancreatic cancer	6.27e-06	0.000277	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—AKT1—pancreatic cancer	6.25e-06	0.000276	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—AKT1—pancreatic cancer	6.25e-06	0.000276	CbGpPWpGaD
Procainamide—SLC22A2—Transmission across Chemical Synapses—HRAS—pancreatic cancer	6.2e-06	0.000274	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—GCG—pancreatic cancer	6.2e-06	0.000274	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—EGFR—pancreatic cancer	6.2e-06	0.000274	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—DPYD—pancreatic cancer	6.17e-06	0.000273	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	6.12e-06	0.00027	CbGpPWpGaD
Procainamide—ACHE—Metabolism—CD44—pancreatic cancer	6.11e-06	0.00027	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—TYMS—pancreatic cancer	6.02e-06	0.000266	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	5.98e-06	0.000264	CbGpPWpGaD
Procainamide—DNMT1—Gene Expression—MYC—pancreatic cancer	5.98e-06	0.000264	CbGpPWpGaD
Procainamide—ACHE—Metabolism of proteins—MMP2—pancreatic cancer	5.98e-06	0.000264	CbGpPWpGaD
Procainamide—ACHE—Neuronal System—HRAS—pancreatic cancer	5.97e-06	0.000264	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—DTX4—pancreatic cancer	5.95e-06	0.000263	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—GLI1—pancreatic cancer	5.95e-06	0.000263	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	5.93e-06	0.000262	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—AGTR1—pancreatic cancer	5.92e-06	0.000261	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—TNF—pancreatic cancer	5.9e-06	0.000261	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—SLC2A2—pancreatic cancer	5.86e-06	0.000259	CbGpPWpGaD
Procainamide—ACHE—Metabolism—GCG—pancreatic cancer	5.86e-06	0.000259	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—KRAS—pancreatic cancer	5.85e-06	0.000259	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—CNR1—pancreatic cancer	5.83e-06	0.000258	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—NRP1—pancreatic cancer	5.79e-06	0.000256	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PPP2R5B—pancreatic cancer	5.79e-06	0.000256	CbGpPWpGaD
Procainamide—SLC22A1—Transmission across Chemical Synapses—HRAS—pancreatic cancer	5.78e-06	0.000255	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PRSS1—pancreatic cancer	5.67e-06	0.000251	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—GCG—pancreatic cancer	5.63e-06	0.000249	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—HEY2—pancreatic cancer	5.58e-06	0.000246	CbGpPWpGaD
Procainamide—ACHE—Metabolism—STK11—pancreatic cancer	5.51e-06	0.000243	CbGpPWpGaD
Procainamide—BCHE—Metabolism—CD44—pancreatic cancer	5.45e-06	0.000241	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—GAST—pancreatic cancer	5.45e-06	0.000241	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—AGTR1—pancreatic cancer	5.37e-06	0.000237	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	5.34e-06	0.000236	CbGpPWpGaD
Procainamide—BCHE—Metabolism of proteins—MMP2—pancreatic cancer	5.33e-06	0.000236	CbGpPWpGaD
Procainamide—BCHE—Neuronal System—HRAS—pancreatic cancer	5.32e-06	0.000235	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	5.29e-06	0.000234	CbGpPWpGaD
Procainamide—BCHE—Metabolism—GCG—pancreatic cancer	5.22e-06	0.000231	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	5.17e-06	0.000228	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—SCT—pancreatic cancer	5.16e-06	0.000228	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—HEY1—pancreatic cancer	5.16e-06	0.000228	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—HRAS—pancreatic cancer	4.98e-06	0.00022	CbGpPWpGaD
Procainamide—ACHE—Metabolism of proteins—CXCL8—pancreatic cancer	4.97e-06	0.000219	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CCK—pancreatic cancer	4.92e-06	0.000218	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—ARG2—pancreatic cancer	4.92e-06	0.000217	CbGpPWpGaD
Procainamide—BCHE—Metabolism—STK11—pancreatic cancer	4.91e-06	0.000217	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—APOE—pancreatic cancer	4.89e-06	0.000216	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—CD44—pancreatic cancer	4.87e-06	0.000215	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CNR2—pancreatic cancer	4.8e-06	0.000212	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—GLP1R—pancreatic cancer	4.8e-06	0.000212	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—CXCL8—pancreatic cancer	4.8e-06	0.000212	CbGpPWpGaD
Procainamide—SLC22A2—Neuronal System—HRAS—pancreatic cancer	4.75e-06	0.00021	CbGpPWpGaD
Procainamide—ACHE—Metabolism—TYMS—pancreatic cancer	4.74e-06	0.000209	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CCKAR—pancreatic cancer	4.72e-06	0.000209	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—GCG—pancreatic cancer	4.67e-06	0.000206	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	4.61e-06	0.000204	CbGpPWpGaD
Procainamide—ACHE—Metabolism of proteins—CTNNB1—pancreatic cancer	4.58e-06	0.000202	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—JAG2—pancreatic cancer	4.58e-06	0.000202	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—CD44—pancreatic cancer	4.54e-06	0.0002	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MEN1—pancreatic cancer	4.51e-06	0.000199	CbGpPWpGaD
Procainamide—BCHE—Metabolism of proteins—CXCL8—pancreatic cancer	4.43e-06	0.000196	CbGpPWpGaD
Procainamide—SLC22A1—Neuronal System—HRAS—pancreatic cancer	4.43e-06	0.000196	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PIK3CG—pancreatic cancer	4.42e-06	0.000195	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—AKT1—pancreatic cancer	4.39e-06	0.000194	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—STK11—pancreatic cancer	4.39e-06	0.000194	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—GCG—pancreatic cancer	4.35e-06	0.000192	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—SHH—pancreatic cancer	4.3e-06	0.00019	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—TYMP—pancreatic cancer	4.3e-06	0.00019	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—NOTCH4—pancreatic cancer	4.28e-06	0.000189	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PPARG—pancreatic cancer	4.26e-06	0.000188	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—IAPP—pancreatic cancer	4.25e-06	0.000188	CbGpPWpGaD
Procainamide—BCHE—Metabolism—TYMS—pancreatic cancer	4.23e-06	0.000187	CbGpPWpGaD
Procainamide—DNMT1—Gene Expression—AKT1—pancreatic cancer	4.15e-06	0.000183	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—STK11—pancreatic cancer	4.09e-06	0.000181	CbGpPWpGaD
Procainamide—BCHE—Metabolism of proteins—CTNNB1—pancreatic cancer	4.09e-06	0.000181	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PTHLH—pancreatic cancer	4.08e-06	0.00018	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PTCH1—pancreatic cancer	4.08e-06	0.00018	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PIK3CD—pancreatic cancer	3.88e-06	0.000172	CbGpPWpGaD
Procainamide—ACHE—Metabolism—APOE—pancreatic cancer	3.85e-06	0.00017	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—TYMS—pancreatic cancer	3.77e-06	0.000167	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—SST—pancreatic cancer	3.73e-06	0.000165	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—PIK3CG—pancreatic cancer	3.68e-06	0.000163	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—JAG1—pancreatic cancer	3.65e-06	0.000161	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	3.65e-06	0.000161	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—NOTCH3—pancreatic cancer	3.64e-06	0.000161	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—TYMS—pancreatic cancer	3.52e-06	0.000155	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PIK3CG—pancreatic cancer	3.48e-06	0.000154	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—GLP1R—pancreatic cancer	3.47e-06	0.000153	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CNR1—pancreatic cancer	3.44e-06	0.000152	CbGpPWpGaD
Procainamide—BCHE—Metabolism—APOE—pancreatic cancer	3.44e-06	0.000152	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—DPYD—pancreatic cancer	3.41e-06	0.000151	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PIK3CB—pancreatic cancer	3.38e-06	0.00015	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PPARG—pancreatic cancer	3.36e-06	0.000148	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PTGS2—pancreatic cancer	3.35e-06	0.000148	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—PIK3CG—pancreatic cancer	3.34e-06	0.000148	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—GCG—pancreatic cancer	3.33e-06	0.000147	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	3.25e-06	0.000144	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—PIK3CD—pancreatic cancer	3.24e-06	0.000143	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—SLC2A2—pancreatic cancer	3.24e-06	0.000143	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—AGTR1—pancreatic cancer	3.17e-06	0.00014	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—STK11—pancreatic cancer	3.13e-06	0.000138	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PIK3CG—pancreatic cancer	3.1e-06	0.000137	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—APOE—pancreatic cancer	3.07e-06	0.000136	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PIK3CD—pancreatic cancer	3.06e-06	0.000135	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PPARG—pancreatic cancer	2.99e-06	0.000132	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—PIK3CD—pancreatic cancer	2.94e-06	0.00013	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PTEN—pancreatic cancer	2.92e-06	0.000129	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—APOE—pancreatic cancer	2.86e-06	0.000126	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—PIK3CB—pancreatic cancer	2.82e-06	0.000125	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PIK3CG—pancreatic cancer	2.77e-06	0.000122	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—SMAD4—pancreatic cancer	2.74e-06	0.000121	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PIK3CD—pancreatic cancer	2.73e-06	0.00012	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—CXCL8—pancreatic cancer	2.71e-06	0.00012	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—HES1—pancreatic cancer	2.67e-06	0.000118	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PPARG—pancreatic cancer	2.67e-06	0.000118	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PIK3CB—pancreatic cancer	2.66e-06	0.000118	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PTGS2—pancreatic cancer	2.64e-06	0.000117	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PIK3CG—pancreatic cancer	2.58e-06	0.000114	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—PIK3CB—pancreatic cancer	2.56e-06	0.000113	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—CD44—pancreatic cancer	2.51e-06	0.000111	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PPARG—pancreatic cancer	2.49e-06	0.00011	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—CXCL8—pancreatic cancer	2.46e-06	0.000109	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PIK3CD—pancreatic cancer	2.44e-06	0.000108	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—GCG—pancreatic cancer	2.4e-06	0.000106	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PIK3CB—pancreatic cancer	2.38e-06	0.000105	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PTGS2—pancreatic cancer	2.35e-06	0.000104	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—TERT—pancreatic cancer	2.34e-06	0.000104	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PTEN—pancreatic cancer	2.3e-06	0.000102	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PIK3CD—pancreatic cancer	2.27e-06	0.0001	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—STK11—pancreatic cancer	2.26e-06	9.98e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—HIF1A—pancreatic cancer	2.24e-06	9.9e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—TSC2—pancreatic cancer	2.24e-06	9.88e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—APOE—pancreatic cancer	2.19e-06	9.67e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—KDR—pancreatic cancer	2.14e-06	9.47e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PIK3CB—pancreatic cancer	2.12e-06	9.38e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PTGS2—pancreatic cancer	2.1e-06	9.29e-05	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PIK3CA—pancreatic cancer	2.06e-06	9.11e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PTEN—pancreatic cancer	2.05e-06	9.07e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—NFKBIA—pancreatic cancer	2.04e-06	9.01e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—NOTCH1—pancreatic cancer	2.02e-06	8.92e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PIK3CB—pancreatic cancer	1.98e-06	8.74e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PIK3CG—pancreatic cancer	1.97e-06	8.72e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—NRAS—pancreatic cancer	1.97e-06	8.72e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PTGS2—pancreatic cancer	1.96e-06	8.66e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—EGF—pancreatic cancer	1.95e-06	8.62e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—TYMS—pancreatic cancer	1.94e-06	8.58e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PTEN—pancreatic cancer	1.83e-06	8.1e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—EGFR—pancreatic cancer	1.8e-06	7.95e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PIK3CD—pancreatic cancer	1.74e-06	7.67e-05	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.72e-06	7.6e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PTEN—pancreatic cancer	1.71e-06	7.55e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—KRAS—pancreatic cancer	1.7e-06	7.51e-05	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—AKT1—pancreatic cancer	1.69e-06	7.45e-05	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PIK3CA—pancreatic cancer	1.62e-06	7.17e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—APOE—pancreatic cancer	1.58e-06	6.98e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—PIK3CA—pancreatic cancer	1.56e-06	6.9e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PIK3CB—pancreatic cancer	1.51e-06	6.69e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CXCL8—pancreatic cancer	1.45e-06	6.42e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PIK3CA—pancreatic cancer	1.45e-06	6.4e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—HRAS—pancreatic cancer	1.44e-06	6.38e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	1.43e-06	6.3e-05	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—AKT1—pancreatic cancer	1.4e-06	6.21e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CASP3—pancreatic cancer	1.39e-06	6.15e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PPARG—pancreatic cancer	1.38e-06	6.08e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CCND1—pancreatic cancer	1.35e-06	5.99e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CTNNB1—pancreatic cancer	1.34e-06	5.93e-05	CbGpPWpGaD
Procainamide—ACHE—Metabolism—AKT1—pancreatic cancer	1.33e-06	5.86e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MMP9—pancreatic cancer	1.32e-06	5.81e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PTEN—pancreatic cancer	1.31e-06	5.78e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PIK3CA—pancreatic cancer	1.29e-06	5.72e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—AKT1—pancreatic cancer	1.28e-06	5.64e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	1.25e-06	5.54e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—SRC—pancreatic cancer	1.21e-06	5.36e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PIK3CA—pancreatic cancer	1.21e-06	5.33e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—AKT1—pancreatic cancer	1.18e-06	5.23e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—VEGFA—pancreatic cancer	1.18e-06	5.22e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—STAT3—pancreatic cancer	1.17e-06	5.17e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—NRAS—pancreatic cancer	1.17e-06	5.15e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	1.09e-06	4.83e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MYC—pancreatic cancer	1.09e-06	4.8e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—TGFB1—pancreatic cancer	1.08e-06	4.79e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PTGS2—pancreatic cancer	1.08e-06	4.78e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—EGFR—pancreatic cancer	1.06e-06	4.7e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—AKT1—pancreatic cancer	1.06e-06	4.67e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—KRAS—pancreatic cancer	1e-06	4.44e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—AKT1—pancreatic cancer	9.85e-07	4.35e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PTEN—pancreatic cancer	9.44e-07	4.17e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PIK3CA—pancreatic cancer	9.22e-07	4.08e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—TP53—pancreatic cancer	8.92e-07	3.94e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—HRAS—pancreatic cancer	8.53e-07	3.77e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—AKT1—pancreatic cancer	7.54e-07	3.33e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	6.66e-07	2.94e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—AKT1—pancreatic cancer	5.44e-07	2.4e-05	CbGpPWpGaD
